Balyasny Asset Management
BBIO icon

Balyasny Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Balyasny Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,300
Closed -$941K – 2896
2025
Q4 		$941K Hold
12,300
– – ﹤0.01% 2226
2025
Q3 		$639K Sell
12,300
-400
-3% -$19.5K ﹤0.01% 2290
2025
Q2 		$548K Hold
12,700
– – ﹤0.01% 2260
2025
Q1 		$439K Buy
+12,700
New +$428K ﹤0.01% 2320
2024
Q4 		– Sell
-19,800
Closed -$504K – 2737
2024
Q3 		$504K Buy
+19,800
New +$520K ﹤0.01% 2252

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's BBIO Position: Q1 2026 in Review

Balyasny Asset Management increased its BridgeBio Pharma (BBIO) stake by 49% in Q1 2026, buying an estimated $8.39M and bringing the position to 350,096 shares worth $26M. The position accounts for 0.03% of the portfolio, ranked #586.

Balyasny Asset Management first reported a position in BBIO in Q1 2022 and has held it in 9 quarters since. The position peaked at $70.9M in Q2 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Balyasny Asset Management held 350,096 shares of BridgeBio Pharma worth $26M as of Q1 2026.
  • Balyasny Asset Management bought 115,707 BridgeBio Pharma shares in Q1 2026, an estimated $8.39M.
  • BridgeBio Pharma made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #586 holding.
  • Balyasny Asset Management first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 9 quarters since.
  • Balyasny Asset Management's BridgeBio Pharma position peaked at $70.9M in Q2 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.